Recommendations on Breast Cancer Screening and Prevention in the Context of Implementing Risk Stratification: Impending Changes to Current Policies

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2017 Jan 5

PMID 28050152

Citations 24

Authors

J Gagnon

E Levesque

F Borduas

J Chiquette

C Diorio

N Duchesne

M Dumais

L Eloy

W Foulkes

N Gervais

L Lalonde

B LEsperance

S Meterissian

L Provencher

J Richard

C Savard

I Trop

N Wong

B M Knoppers

J Simard

Affiliations

Soon will be listed here.

Abstract

In recent years, risk stratification has sparked interest as an innovative approach to disease screening and prevention. The approach effectively personalizes individual risk, opening the way to screening and prevention interventions that are adapted to subpopulations. The international perspective project, which is developing risk stratification for breast cancer, aims to support the integration of its screening approach into clinical practice through comprehensive tool-building. Policies and guidelines for risk stratification-unlike those for population screening programs, which are currently well regulated-are still under development. Indeed, the development of guidelines for risk stratification reflects the translational aspects of perspective. Here, we describe the risk stratification process that was devised in the context of perspective, and we then explain the consensus-based method used to develop recommendations for breast cancer screening and prevention in a risk-stratification approach. Lastly, we discuss how the recommendations might affect current screening policies.

Citing Articles

Clinical guidelines for the management of mammographic density: a systematic review of breast screening guidelines worldwide.

Isautier J, Houssami N, Hadlow C, Marinovich M, Hope S, Zackrisson S JNCI Cancer Spectr. 2024; 8(6).

PMID: 39392432 PMC: 11578290. DOI: 10.1093/jncics/pkae103.

Plasma metabolomics profiles and breast cancer risk.

Wu H, Lai Y, Liao Y, Deyssenroth M, Miller G, Santella R Breast Cancer Res. 2024; 26(1):141.

PMID: 39385226 PMC: 11463119. DOI: 10.1186/s13058-024-01896-5.

Acceptability and appropriateness of a risk-tailored organised melanoma screening program: Qualitative interviews with key informants.

Dunlop K, Keogh L, Smith A, Aranda S, Aitken J, Watts C PLoS One. 2023; 18(12):e0287591.

PMID: 38091281 PMC: 10718433. DOI: 10.1371/journal.pone.0287591.

A scoping review of programme specific mammographic breast density related guidelines and practices within breast screening programmes.

ODriscoll J, Burke A, Mooney T, Phelan N, Baldelli P, Smith A Eur J Radiol Open. 2023; 11:100510.

PMID: 37560166 PMC: 10407884. DOI: 10.1016/j.ejro.2023.100510.

Canadian Healthcare Professionals' Views and Attitudes toward Risk-Stratified Breast Cancer Screening.

Lapointe J, Cote J, Mbuya-Bienge C, Dorval M, Pashayan N, Chiquette J J Pers Med. 2023; 13(7).

PMID: 37511640 PMC: 10381377. DOI: 10.3390/jpm13071027.

References

Fachal L, Dunning A . From candidate gene studies to GWAS and post-GWAS analyses in breast cancer. Curr Opin Genet Dev. 2015; 30:32-41. DOI: 10.1016/j.gde.2015.01.004. View

Provencher L, Hogue J, Desbiens C, Poirier B, Poirier E, Boudreau D . Is clinical breast examination important for breast cancer detection?. Curr Oncol. 2016; 23(4):e332-9. PMC: 4974039. DOI: 10.3747/co.23.2881. View

Meisel S, Pashayan N, Rahman B, Side L, Fraser L, Gessler S . Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK. Breast. 2015; 24(3):237-41. PMC: 4427278. DOI: 10.1016/j.breast.2015.02.001. View

Evans D, Donnelly L, Harkness E, Astley S, Stavrinos P, Dawe S . Breast cancer risk feedback to women in the UK NHS breast screening population. Br J Cancer. 2016; 114(9):1045-52. PMC: 4984905. DOI: 10.1038/bjc.2016.56. View

Mavaddat N, Pharoah P, Michailidou K, Tyrer J, Brook M, Bolla M . Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015; 107(5). PMC: 4754625. DOI: 10.1093/jnci/djv036. View

Lee A, Cunningham A, Tischkowitz M, Simard J, Pharoah P, Easton D . Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genet Med. 2016; 18(12):1190-1198. PMC: 5086091. DOI: 10.1038/gim.2016.31. View

Garcia-Closas M, Gunsoy N, Chatterjee N . Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer. J Natl Cancer Inst. 2014; 106(11). PMC: 4271030. DOI: 10.1093/jnci/dju305. View

Schully S, Khoury M . What is translational genomics? An expanded research agenda for improving individual and population health. Appl Transl Genom. 2016; 3(4):82-83. PMC: 4694629. DOI: 10.1016/j.atg.2014.09.006. View

Easton D, Pharoah P, Antoniou A, Tischkowitz M, Tavtigian S, Nathanson K . Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015; 372(23):2243-57. PMC: 4610139. DOI: 10.1056/NEJMsr1501341. View

10.

Cunningham A, Antoniou A, Easton D . Clinical software development for the Web: lessons learned from the BOADICEA project. BMC Med Inform Decis Mak. 2012; 12:30. PMC: 3507671. DOI: 10.1186/1472-6947-12-30. View

11.

. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012; 380(9855):1778-86. DOI: 10.1016/S0140-6736(12)61611-0. View

12.

Lee A, Cunningham A, Kuchenbaecker K, Mavaddat N, Easton D, Antoniou A . BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer. 2013; 110(2):535-45. PMC: 3899766. DOI: 10.1038/bjc.2013.730. View

13.

Mariotto A, Feuer E, Harlan L, Wun L, Johnson K, Abrams J . Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst. 2002; 94(21):1626-34. DOI: 10.1093/jnci/94.21.1626. View

14.

Pharoah P, Antoniou A, Easton D, Ponder B . Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. 2008; 358(26):2796-803. DOI: 10.1056/NEJMsa0708739. View

15.

Howell A, Anderson A, Clarke R, Duffy S, Evans D, Garcia-Closas M . Risk determination and prevention of breast cancer. Breast Cancer Res. 2014; 16(5):446. PMC: 4303126. DOI: 10.1186/s13058-014-0446-2. View

16.

Peto J, Mack T . High constant incidence in twins and other relatives of women with breast cancer. Nat Genet. 2000; 26(4):411-4. DOI: 10.1038/82533. View

17.

Harbeck N, Thomssen C, Gnant M . St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast Care (Basel). 2013; 8(2):102-9. PMC: 3683952. DOI: 10.1159/000351193. View

18.

Mavaddat N, Rebbeck T, Lakhani S, Easton D, Antoniou A . Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res. 2010; 12(3):R28. PMC: 2917017. DOI: 10.1186/bcr2576. View

19.

Bevers T, Anderson B, Bonaccio E, Buys S, Buys S, Daly M . NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009; 7(10):1060-96. DOI: 10.6004/jnccn.2009.0070. View

20.

. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001; 358(9291):1389-99. DOI: 10.1016/S0140-6736(01)06524-2. View